GALIDESIVIR TRIAL | BCRX Message Board Posts

BioCryst Pharmaceuticals Inc.

  BCRX website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left)  5-yrs @ $199 (only 31 left)  2-yrs @ $99 (only 29 left)


  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10145 of 12373  at  9/20/2019 9:46:05 AM  by

capecod3


 In response to msg 10144 by  lsquared
view thread

Re: GALIDESIVIR TRIAL

 Very negative comment. Do you have any confidence in this management to bring any product to market successfully?  Their track record to date is dismal. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 128
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10146 Re: GALIDESIVIR TRIAL lsquared 0 9/20/2019 9:55:00 AM






Financial Market Data provided by
.


Loading...